Lupin Limited

Lupin is an Indian pharmaceutical company headquartered in India. It engages in the research, development, manufacture, and marketing of a broad portfolio of pharmaceutical products. Its offerings include generic formulations, branded generics, and active pharmaceutical ingredients. The company serves patients and healthcare providers across various therapeutic areas such as cardiovascular, diabetes, respiratory, and anti-infectives. Lupin’s products are distributed through a network that reaches multiple countries, supporting both domestic and international markets.

The organization places a strong emphasis on generic drug development, leveraging its capabilities in complex molecule synthesis and formulation technology. Lupin maintains integrated manufacturing facilities that adhere to stringent global regulatory standards, enabling it to supply regulated markets like the United States and Europe. Its research and development efforts focus on creating cost‑effective alternatives to originator medicines while also exploring novel drug delivery systems. These competencies have positioned Lupin as a notable player in the generic pharmaceutical sector, particularly in emerging economies.

In November 2020, Lupin reported a cybersecurity breach that affected several of its internal IT systems. The incident occurred shortly after a ransomware attack on another Indian pharmaceutical firm, highlighting heightened cyber threats to the healthcare sector during the COVID‑19 pandemic. Although the breach disrupted some internal processes, the company stated that its core manufacturing and supply chain operations remained unaffected. Lupin’s response included containment measures, forensic analysis, and reinforcement of its cybersecurity posture to prevent recurrence.